About Melinta Therapeutics
Melinta Therapeutics is a company based in Morristown (United States) founded in 2000 was acquired by CorMedix in August 2025. Melinta Therapeutics has raised $186 million across 15 funding rounds from investors including Hercules Capital, Sanofi and Warburg Pincus. Melinta Therapeutics offers products and services including Innovative Therapies and Portfolio Products. Melinta Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others.
- Headquarter Morristown, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Melinta Therapeutics, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$186 M (USD)
in 15 rounds
-
Latest Funding Round
$75 M (USD), Post-IPO
Feb 22, 2019
-
Investors
Hercules Capital
& 16 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Melinta Therapeutics
Melinta Therapeutics offers a comprehensive portfolio of products and services, including Innovative Therapies and Portfolio Products.
Therapies targeting acute and life-threatening illnesses for patient care.
Commercial-stage products for expanding healthcare applications.
People of Melinta Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Melinta Therapeutics
Melinta Therapeutics has successfully raised a total of $186M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Melinta Therapeutics
Melinta Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Sanofi and Warburg Pincus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for Melinta Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Melinta Therapeutics
Investment portfolio details for Melinta Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Melinta Therapeutics
Detailed financials for Melinta Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Melinta Therapeutics Comparisons
Peer comparison for Melinta Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Melinta Therapeutics
Melinta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Iterum Therapeutics, Adaptive Phage Therapeutics and Cubist Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of Melinta Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Melinta Therapeutics
Complete news archive for Melinta Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Melinta Therapeutics
Melinta Therapeutics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Melinta Therapeutics is headquartered in Morristown, United States. It is registered at Morristown, New Jersey, United States.
Christine Ann Miller is the current CEO of Melinta Therapeutics.
Melinta Therapeutics is a funded company, having raised a total of $186M across 15 funding rounds to date.
Melinta Therapeutics is developing bacterial ribosome-targeting drugs for MDR infections. The company has commercialized its antibiotic, delafloxacin for acute bacterial skin and skin structure infections (Staphylococcus strains, Streptococcus strains, Enterococcus strain, E.coli, Enterobacter cloacae, Klebsiella pneumoniae, and P.aeruginosa), community-acquired bacterial pneumonia (CABP), and Complicated Urinary Tract Infections (cUTI). It is also developing a new class of antibiotics designed to overcome the resistant ESKAPE pathogens that cause hospital infections.
Melinta Therapeutics's top competitors include Spero Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
Melinta Therapeutics offers Innovative Therapies and Portfolio Products.
Melinta Therapeutics has 17 investors. Key investors include Hercules Capital, Sanofi, Warburg Pincus, CorMedix, and Vatera Healthcare Partners.